BridgeBio Oncology Therapeutics (BBOT) Shares Outstanding (2023 - 2026)
BridgeBio Oncology Therapeutics (BBOT) posted Shares Outstanding (Entity) of $80032.0 for Q1 2026, down 99.74% sequentially from $31.1 million in Q4 2025, and down 99.58% YoY from $18.9 million in Q1 2025.
BridgeBio Oncology Therapeutics (BBOT) Shares Outstanding (2023 - 2026) Analysis & Trends
BridgeBio Oncology Therapeutics has reported Shares Outstanding (Entity) for 4 years, with the latest figure at $80032.0 in Q1 2026.
- Quarterly Shares Outstanding (Entity) fell 99.58% year-over-year to $80032.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80032.0 (down 99.58% YoY) and the FY2025 annual result came in at $31.1 million, up 87.22% from the prior year.
- Shares Outstanding (Entity) fell to $80032.0 in Q1 2026 per BBOT's latest filing, from $31.1 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $43.5 million in Q3 2025 and troughed at $80032.0 in Q1 2026.
- A 4-year average of $18.1 million and a median of $18.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2024 and 2026: Shares Outstanding (Entity) soared 261.65% in 2024, then sank 99.58% in 2026.
- Over 4 years, Shares Outstanding (Entity) stood at $4.6 million in 2023, then jumped by 261.65% to $16.6 million in 2024, then surged by 87.22% to $31.1 million in 2025, then plunged by 99.74% to $80032.0 in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $80032.0, $31.1 million, and $43.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | BridgeBio Oncology Therapeutics | 726.38 Mn | 500.67 Mn | - | 80.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 80.05 Mn |
| Mar 31, 2026 | 80,032.00 |
| Dec 31, 2025 | 31.14 Mn |
| Sep 30, 2025 | 43.49 Mn |
| Jun 30, 2025 | 18.91 Mn |
| Mar 31, 2025 | 18.91 Mn |
| Dec 31, 2024 | 16.64 Mn |
| Sep 30, 2024 | 18.91 Mn |
| Jun 30, 2024 | 18.91 Mn |
| Mar 31, 2024 | 9.87 Mn |
| Dec 31, 2023 | 4.00 Mn |